Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:INFUNASDAQ:MODDNASDAQ:OBIONASDAQ:SGHT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINFUInfuSystem$5.22+0.6%$5.27$4.61▼$9.97$109.70M1.7395,161 shs312,560 shsMODDModular Medical$0.87-0.3%$0.96$0.68▼$2.65$47.32M0.33207,887 shs41,755 shsOBIOOrchestra BioMed$2.95+4.6%$3.01$2.37▼$8.87$113.02M0.67164,528 shs200,021 shsSGHTSight Sciences$3.61+4.9%$2.86$2.03▼$8.45$186.62M2.41214,445 shs142,448 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINFUInfuSystem+0.58%-13.72%+5.67%-32.99%-30.49%MODDModular Medical-0.31%+2.62%-14.48%+3.85%-44.79%OBIOOrchestra BioMed+4.61%+7.66%+13.03%-35.16%-57.68%SGHTSight Sciences+4.94%+11.42%+16.83%+36.74%-39.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINFUInfuSystem2.3193 of 5 stars2.00.00.00.02.74.21.9MODDModular Medical1.3397 of 5 stars0.05.00.00.02.03.30.0OBIOOrchestra BioMed2.5642 of 5 stars4.63.00.00.01.60.80.0SGHTSight Sciences3.2479 of 5 stars3.14.00.00.02.94.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINFUInfuSystem 4.00Strong Buy$13.00149.04% UpsideMODDModular Medical 0.00N/AN/AN/AOBIOOrchestra BioMed 3.20Buy$14.20381.36% UpsideSGHTSight Sciences 2.29Hold$4.0211.27% UpsideCurrent Analyst Ratings BreakdownLatest MODD, SGHT, OBIO, and INFU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025SGHTSight SciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.20 ➝ $3.605/13/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/9/2025SGHTSight SciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$2.50 ➝ $3.005/8/2025INFUInfuSystemB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/5/2025OBIOOrchestra BioMedBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $12.004/23/2025OBIOOrchestra BioMedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/22/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/9/2025SGHTSight SciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/4/2025OBIOOrchestra BioMedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.004/3/2025OBIOOrchestra BioMedB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/1/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINFUInfuSystem$137.58M0.80$0.41 per share12.79$2.47 per share2.11MODDModular MedicalN/AN/AN/AN/A$0.25 per shareN/AOBIOOrchestra BioMed$2.89M39.16N/AN/A$1.90 per share1.55SGHTSight Sciences$78.11M2.39N/AN/A$2.47 per share1.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINFUInfuSystem$870K$0.1487.0116.84N/A1.12%2.78%1.41%N/AMODDModular Medical-$17.47M-$0.53N/A∞N/AN/A-197.97%-162.31%6/20/2025 (Estimated)OBIOOrchestra BioMed-$49.12M-$1.78N/AN/AN/A-2,179.33%-107.04%-70.88%N/ASGHTSight Sciences-$55.55M-$0.98N/AN/AN/A-63.30%-47.28%-32.72%8/7/2025 (Estimated)Latest MODD, SGHT, OBIO, and INFU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025OBIOOrchestra BioMed-$0.46-$0.49-$0.03-$0.49$0.39 million$0.87 million5/8/2025Q1 2025SGHTSight Sciences-$0.29-$0.28+$0.01-$0.28$16.51 million$17.51 million3/31/2025Q4 2024OBIOOrchestra BioMed-$0.43-$0.43N/A-$0.43$0.79 million$0.25 million3/5/2025Q4 2024SGHTSight Sciences-$0.22-$0.23-$0.01-$0.23$18.98 million$19.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINFUInfuSystemN/AN/AN/AN/AN/AMODDModular MedicalN/AN/AN/AN/AN/AOBIOOrchestra BioMedN/AN/AN/AN/AN/ASGHTSight SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINFUInfuSystem0.501.981.59MODDModular MedicalN/A5.305.30OBIOOrchestra BioMedN/A4.234.21SGHTSight Sciences0.3610.189.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINFUInfuSystem71.13%MODDModular Medical27.47%OBIOOrchestra BioMed53.55%SGHTSight Sciences55.51%Insider OwnershipCompanyInsider OwnershipINFUInfuSystem11.40%MODDModular Medical20.46%OBIOOrchestra BioMed8.10%SGHTSight Sciences30.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINFUInfuSystem41021.02 million19.10 millionOptionableMODDModular Medical2054.25 million32.35 millionNot OptionableOBIOOrchestra BioMed438.31 million35.47 millionNot OptionableSGHTSight Sciences21051.70 million36.09 millionOptionableMODD, SGHT, OBIO, and INFU HeadlinesRecent News About These CompaniesD. E. Shaw & Co. Inc. Acquires 88,738 Shares of Sight Sciences, Inc. (NASDAQ:SGHT)May 25, 2025 | marketbeat.comCitigroup Reaffirms Neutral Rating for Sight Sciences (NASDAQ:SGHT)May 24, 2025 | americanbankingnews.comJacobs Levy Equity Management Inc. Sells 135,268 Shares of Sight Sciences, Inc. (NASDAQ:SGHT)May 21, 2025 | marketbeat.comSight Sciences (NASDAQ:SGHT) versus Merit Medical Systems (NASDAQ:MMSI) Financial SurveyMay 20, 2025 | americanbankingnews.comSight Sciences, Inc. (NASDAQ:SGHT) Shares Purchased by Dimensional Fund Advisors LPMay 18, 2025 | marketbeat.comProsight Management LP Acquires 377,625 Shares of Sight Sciences, Inc. (NASDAQ:SGHT)May 17, 2025 | marketbeat.comSight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27thMay 14, 2025 | globenewswire.comBrokers Set Expectations for Sight Sciences Q1 EarningsMay 13, 2025 | marketbeat.comSight Sciences stock holds as Needham reiterates ratingMay 11, 2025 | uk.investing.comSight Sciences, Inc. (SGHT) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comSight Sciences, Inc. (NASDAQ:SGHT) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comSight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue GuidanceMay 10, 2025 | finance.yahoo.comSight Sciences (SGHT) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 8, 2025 | zacks.comSight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comSight Sciences, Inc. (NASDAQ:SGHT) Receives Average Recommendation of "Hold" from AnalystsMay 6, 2025 | marketbeat.comSight Sciences, Inc. (NASDAQ:SGHT) Shares Acquired by Renaissance Technologies LLCApril 30, 2025 | marketbeat.comWhy Sight Sciences, Inc.’s (SGHT) Stock Is Down 5.02%April 26, 2025 | aaii.comSight Sciences appoints new board memberApril 24, 2025 | investing.comSight Sciences, Inc. to Report First Quarter Financial Results on May 8, 2025April 24, 2025 | quiverquant.comSight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025April 24, 2025 | globenewswire.comSight Sciences Announces the Release of its Sustainability ReportApril 23, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMODD, SGHT, OBIO, and INFU Company DescriptionsInfuSystem NYSE:INFU$5.22 +0.03 (+0.58%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$5.37 +0.15 (+2.87%) As of 04:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.Modular Medical NASDAQ:MODD$0.87 0.00 (-0.31%) Closing price 05/28/2025 03:59 PM EasternExtended Trading$0.86 -0.02 (-1.75%) As of 05/28/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Modular Medical, Inc. operates as a medical device company. It focuses on the design, development, and commercialization of insulin pumps. It offers MODD1, a two-part patch pump for type-1 and type-2 diabetes. The company is headquartered in San Diego, California.Orchestra BioMed NASDAQ:OBIO$2.95 +0.13 (+4.61%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$2.98 +0.03 (+1.02%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.Sight Sciences NASDAQ:SGHT$3.61 +0.17 (+4.94%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$3.62 +0.01 (+0.28%) As of 05/28/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
